Anti -PRAME TCR T cell therapy (Adaptimmune)

N/A

Report date: 2023/10/12 14:04:43

Base Information

Drug NameAnti -PRAME TCR T cell therapy (Adaptimmune)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma antigen preferentially expressed in tumors modulators
TargetsMelanoma antigen preferentially expressed in tumors
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Therapeutics PlcGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune Therapeutics Plc
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A